Rhodes Deborah J, O'Connor Michael K, Phillips Stephen W, Smith Robin L, Collins Douglas A
Department of Internal Medicine and Division of Preventive and Occupational Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA.
Mayo Clin Proc. 2005 Jan;80(1):24-30. doi: 10.1016/S0025-6196(11)62953-4.
To determine the sensitivity of molecular breast imaging (MBI) to detect small cancers of the breast.
A cadmium-zinc-telluride gamma camera with a field of view of 20 x 20 cm was used. The detector elements were 2.5 x 2.5 mm. The gamma camera was mounted on a modified mammographic gantry. Between November 2001 and March 2004, we performed MBI on patients who were scheduled to undergo biopsy for a lesion suggestive of malignancy that was smaller than 2 cm on a mammogram. Patients were injected with 20 mCi of technetium Tc 99m sestamibi and underwent imaging immediately after injection. Using light pain-free compression, we obtained craniocaudal and mediolateral oblique views of each breast.
Of the 40 women included in the study, 26 had a total of 36 malignant lesions confirmed at surgery. Of these 36 lesions, 33 were detected by MBI (overall sensitivity, 92%). Of the 22 malignant lesions 1 cm or smaller in diameter, 19 were detected by MBI (sensitivity, 86%). Two patients had false-negative MBI results. Of the 14 malignant lesions larger than 1 cm in diameter, all were identified correctly by MBI. In 4 patients, MBI identified additional lesions not seen on mammography that were confirmed subsequently on magnetic resonance imaging and were true-positive cases at surgery. Three of these patients had lesions in the breast contralateral to the breast containing the initial mammographic finding suggestive of malignancy. Of 14 patients with no evidence of cancer at biopsy or surgery, 9 had true-negative (normal) scans and 5 had false-positive scans on MBI. False-positive results included benign fibroadenoma (2 patients), inflammatory fat necrosis (1 patient), benign breast parenchyma (1 patient), and complex sclerosing lesion (1 patient).
This prototype gamma camera system for MBI reliably detects malignant breast lesions smaller than 2 cm. Furthermore, we obtained the highest sensitivity (86%) yet reported for the detection of lesions smaller than 1 cm. These results suggest an important role for MBI, particularly for women in whom the sensitivity of mammography is reduced by the density of the breast parenchyma.
确定分子乳腺成像(MBI)检测乳腺小癌的敏感性。
使用一台视野为20×20 cm的碲镉汞γ相机。探测器元件为2.5×2.5 mm。γ相机安装在改良的乳腺X线摄影机架上。在2001年11月至2004年3月期间,我们对因乳腺X线摄影显示有小于2 cm的可疑恶性病变而计划接受活检的患者进行了MBI检查。患者注射20 mCi的锝Tc 99m甲氧基异丁基异腈,并在注射后立即进行成像。使用轻度无痛压迫,获取每个乳房的头尾位和内外斜位图像。
在纳入研究的40名女性中,26名患者共36个恶性病变在手术中得到证实。在这36个病变中,33个被MBI检测到(总体敏感性为92%)。在直径1 cm或更小的22个恶性病变中,19个被MBI检测到(敏感性为86%)。两名患者MBI结果为假阴性。在直径大于1 cm的14个恶性病变中,所有病变均被MBI正确识别。在4名患者中,MBI发现了乳腺X线摄影未显示的额外病变,这些病变随后在磁共振成像中得到证实,并且在手术中为真阳性病例。其中3名患者的病变位于与最初乳腺X线摄影发现可疑恶性病变的乳房对侧的乳房中。在14名活检或手术时无癌症证据的患者中,9名扫描结果为真阴性(正常),5名在MBI上有假阳性扫描结果。假阳性结果包括良性纤维腺瘤(2例)、炎性脂肪坏死(1例)、良性乳腺实质(1例)和复杂性硬化性病变(1例)。
这种用于MBI的原型γ相机系统能够可靠地检测小于2 cm的乳腺恶性病变。此外,我们获得了迄今报道的检测小于1 cm病变的最高敏感性(86%)。这些结果表明MBI具有重要作用,特别是对于乳腺实质密度降低导致乳腺X线摄影敏感性降低的女性。